Trovagene (TROV) Misses Q1 EPS by 7c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/10/2026

1. SPCX
2. HUM
3. ALHC
4. PEP
5. T
6. CVS
7. UNH
8. SPY
9. SBUX
10. AXP

Go back to Trovagene (TROV) Misses Q1 EPS by 7c

Trovagene Announces First Quarter 2016 Financial Results

May 10, 2016 4:06 PM EDT

SAN DIEGO, May 10, 2016 /PRNewswire/ -- Trovagene, Inc. (NASDAQ: TROV), a developer of cell-free molecular diagnostics, today reported its financial results for the three months ended March 31, 2016.

"I'm thrilled to join Trovagene to drive the development and commercialization of the Company's differentiated molecular diagnostic platform, and to improve the care of cancer patients," said Bill Welch, chief executive officer of Trovagene. "Liquid biopsy for cancer monitoring offers tremendous potential, and our strong balance sheet positions us to execute on our business plan and create... More